WO2017173487A1 - Nanofibrous mat containing ceramic particles with releasable dopant - Google Patents
Nanofibrous mat containing ceramic particles with releasable dopant Download PDFInfo
- Publication number
- WO2017173487A1 WO2017173487A1 PCT/AU2017/050289 AU2017050289W WO2017173487A1 WO 2017173487 A1 WO2017173487 A1 WO 2017173487A1 AU 2017050289 W AU2017050289 W AU 2017050289W WO 2017173487 A1 WO2017173487 A1 WO 2017173487A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lidocaine
- dopant
- nanofibres
- nanofibrous mat
- mat according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
- D01F6/28—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from copolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds
- D01F6/34—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from copolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds comprising unsaturated alcohols, acetals or ketals as the major constituent
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/70—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres
- D04H1/72—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged
- D04H1/728—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/624—Nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2509/00—Medical; Hygiene
- D10B2509/02—Bandages, dressings or absorbent pads
- D10B2509/022—Wound dressings
Definitions
- the present invention relates to a nanofibrous mat containing ceramic particles.
- the ceramic particles releasably encapsulate a dopant that is to be delivered from the nanofibrous mat.
- the invention relates to nanofibrous mats that contain at least one dopant encapsulated in a ceramic matrix.
- the invention also provides nanofibrous mats that contain at least one dopant encapsulated in a ceramic matrix and at least one free dopant, which may be the same as or different to the encapsulated dopant. Methods for the production of the nanofibrous mats are also considered.
- Nanofibres generally considered fibres with diameters of less than 1 m, have the potential to improve many products for numerous applications. They offer unique physical, mechanical, and electrical properties associated with their very high surface area. In that regard, nanofibre-nonwoven mats generally have very small pore sizes compared with commercial textiles.
- Nanofibres are generally suitable for use in the production of nonwoven mat for controlled drug delivery. Electrospun fibres have desirable properties, such as high loading, simultaneous delivery of diverse therapies, ease of operation, and cost-effectiveness, which have expanded their use in drug delivery. Of the various applications, wound-dressing and local cancer treatments are two of the most investigated areas.
- Electrospinning is a technology for the production of nanofibres that employs electrostatic forces to produce ultra-fine fibres with diameters ranging from micrometres down to hundreds of nanometres. This is currently quite well known technology for the production of ultra-fine fibres through the action of an external and internal electric field.
- the electrospinning set-up is composed of a spinning electrode (spinneret), which is connected to a high voltage source.
- the spinneret is usually positively charged and located at a defined distance from the oppositely charged collector.
- Different electrospinning setups can be used, including a horizontal set-up or vertical set-up with the spinneret located above and under the collector respectively.
- Different kinds of collectors can be used for electrospinning depending on the desired structure of the nanofibres.
- Electrospun nanofibers have been successfully used to achieve different controlled drug release profiles, such as immediate, smooth, pulsatile, delayed, and biphasic releases. Drugs can be embedded in the fibre through dissolution or dispersion in the polymer solution.
- Many interesting biological entities for tissue development for example proteins or nucleic acid in nature, do not dissolve in organic solvent and may suffer loss of bioactivity when dispersed in the polymer solution.
- a biodegradable drug-eluting wound dressing from an electrospun nanofibrous matrix potentially offers several advantages over conventional ones. Depending on the wound type and its healing, the most suitable wound dressing system must be used. For rapid wound healing, it is common for different types of wound dressing materials to be used.
- Electrospun drug-loaded nanofibre membranes potentially offer several advantages. Local antibiotics and anaesthetic have the advantage of delivering high drug concentrations to the precise area required, and the total dose of antibiotic applied locally is not normally high enough to produce toxic systemic effects.
- Antibiotic-loaded wound dressings made out of biodegradable polymeric membranes boast a number of further advantages. Firstly, biodegradable membranes provide bactericidal concentrations of antibiotics for the prolonged time needed to completely treat the particular infection. Secondly, versatility with regards to degree of biodegradability from weeks to months may allow many types of infections to be treated. Thirdly, biodegradable membranes dissolve, thus there is no need for removal. As these membranes dissolve slowly, they could potentially provide an in situ scaffold for wounds requiring regeneration of tissues, e.g. the soft tissue or bone defect will slowly fill up with tissue, minimising the need for reconstruction.
- Topical application of drugs with an analgesic effect locally to skin or to surrounding tissues is often used in different pain settings, usually with the aim of blocking or reducing activation of nociceptive nerve endings and propagation of action potential to the central nervous system.
- local anaesthetics which work as voltage gated sodium channel blockers. They are used for surface anaesthesia, where a spray, solution or cream is applied to the skin or to a mucous membrane and the effect is usually short-lived and limited to the area of contact.
- Another method involves infiltration anaesthesia, where local anaesthetic is injected and/or infused into the tissue to be anesthetized.
- Peripheral nerve block is used to anaesthetize the area innervated by a peripheral nerve, in which an injection of a local anaesthetic is made in the vicinity of the affected area.
- local anaesthetics are currently available in the form of solution, cream and patch.
- the solution is used for injections, infiltration and as a spray, while the duration of the analgesic/anaesthetic effect is usually defined by the pharmacological profile of the local anaesthetic used.
- Cream formulations are used directly on the skin, but are difficult to maintain for a longer time period.
- the Lidocaine patch represents a relatively new possibility for local anaesthetic delivery and is used in a number of different clinical settings besides treatment of neuropathic pain.
- a number of new local anaesthetic formulations are now being developed for extended effect and reduced systemic toxicity, using liposomes, polymers and microspheres (Wagh, C. F., L.
- lidocaine-embedded poly([D,L]-lactide-co-glycolide) nanofibres reduced the severity of pain in rats after laminectomies (Tseng, YY, WA Chen, JY Liao, YC Kao And SJ Liu. Biodegradable poly([D,L]-lactide-co-glycolide) nanofibers for the sustainable delivery of Lidocaine into the epidural space after laminectomy. Nanomedicine. 2014, 9, 77-87).
- the nanofibres provided a sustained release of lidocaine for more than 2 weeks, and the local concentration was much higher than the concentration in plasma.
- the present invention relates generally to nanofibrous mats that contain at least one dopant encapsulated in a ceramic matrix, and possibly at least one free dopant, which may be the same as or different to the encapsulated dopant. Methods for the production of the nanofibrous mats are also described.
- nanofibrous mat comprising:
- ceramic particles dispersed throughout said nanofibres and comprising a ceramic matrix and a dopant releasably encapsulated within said ceramic matrix
- ceramic particles are dispersed throughout the nanofibres during electrospinning of the nanofibres, whereby said dopant is protected by said ceramic matrix during said electrospinning.
- a dopant may be incorporated into a nanofibrous mat during electrospinning by protecting the dopant within a ceramic matrix that releasably encapsulates the dopant.
- the encapsulated dopant may be selectively released from the ceramic matrix to achieve its purpose.
- the electrospun nanofibres may be formed from any material suitable for use in electrospinning.
- the electrospun nanofibres may include biodegradable polymers and non-biodegredable polymers.
- the dopant encapsulated inside the particles is poorly soluble in the solvent of the polymeric solution to be electrospun (i.e. water or alcohol or another organic solvent).
- the content of the particles may be prematurely released in the polymer solution and thus incorporated in the fibres as "free drug". It may be acceptable for the particles to be slightly soluble, but preferably not highly soluble.
- the electrospun nanofibres are selected from the group consisting of biocompatible and biodegradable or non-biodegradable synthetic or natural polymers.
- the electrospun nanofibres may be selected from the group consisting of cellulose acetate, collagen, elastin, gelatin, hyaluronic acid, polyacrylonitrile, polycaprolactone, polydioxanone, polyethylene oxide, polyhydroxybutyrate, poly(D-lactide), poly(D,L-lactide-co- caprolactone), poly(D,L-lactide-co-glycolide) (PLGA), polylactide, poly(L- lactide), poly(L-lactide-co-caprolactone-co-glycolide), polypropylene, polytetrafluorethylene, polyvinylpyrolidone, sodium alginate and zein.
- the electrospun nanofibres are formed from polyvinylalcohol (PVA).
- PVA polyvinylalcohol
- a 12 wt.% PVA solution is preferred.
- the ceramic particles dispersed throughout the nanofibres comprise a dopant releasably held within a ceramic matrix.
- the particles may comprise solid, porous spheres, or may take the form of a core with one or more layers surrounding the core. If the latter, the dopant may be located in the core, shell or both. The same or different dopants may be included in the core and shell.
- the ceramic matrix may be a polymerisation and/or condensation and/or crosslinking product of a precursor material. It may be a hydrolysed silane, such as a hydrolysed organosilane. It may comprise an organically modified ceramic, such as an organically modified silica (organo-silica). It may be a ceramic having bound organic groups.
- the bound organic groups may be ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, isooctyl, decyl, dodecyl, cyclohexyl, cylcooctyl or cyclopentyl. These may be substituted (e.g. with functional groups, halogens, aryl groups, etc.) or may be unsubstituted.
- Other suitable organic groups include aryl groups, which may have between about 6 and 14 carbon atoms, and may have for example, 6, 8, 10, 12 or 14 or more than 14 carbon atoms.
- Examples include phenyl, biphenyl, naphthyl and anthracyl. These may each, optionally, be substituted by one or more alkyl groups (e.g. C1 to C6 straight chain or branched alkyl), halogens, functional groups or other substituents.
- the organic group may be an alkenyl or alkynyl or benzyl group.
- the alkenyl or alkynyl group may have between 2 and about 18 carbon atoms, and may be straight chain, branched or (if sufficient carbon atoms are present) cyclic. It may have 1 or more than 1 double bond, or 1 or more than 1 triple bond, and may have a mixture of double and triple bonds.
- the solid matrix may comprise chemical groups derived from a catalyst used in the formation of the ceramic particles, and the groups may be on the surface of the particles.
- a surfactant used in the formation reaction is capable of combining chemically with the precursor material, the matrix may comprise chemical groups derived from the surfactant.
- the precursor material comprises an organotrialkoxysilane
- the catalyst comprises a trialkoxyaminoalkylsilane
- the matrix may comprise aminoalkylsilyl units. These may be distributed evenly or unevenly through the particle. They may be preferentially near the surface of the particle.
- the surfactant may be capable of combining chemically with the precursor material.
- the precursor material comprises an organotrialkoxysilane
- the surfactant comprises trialkoxysilyl functionality
- the matrix may comprise surfactant derived units.
- the surfactant may be adsorbed on the surface of the particle.
- the dopant may be selected from the group consisting of hydrophobic and hydrophilic small molecule drugs such as antibiotics (Chloremphenicol), analgesics (nonsteroidal anti-inflammatory drugs (e.g. diclofenac and ibuprofen), dibucaine, bupivacaine, capsaicin, amitriptyline, glyceryl trinitrate, opioids, menthol, pimecrolimus, and phenytoin), Scopolamine (tropane alkaloid drug) for motion sickness.
- antibiotics Chloremphenicol
- analgesics nonsteroidal anti-inflammatory drugs (e.g. diclofenac and ibuprofen)
- dibucaine e.g. diclofenac and ibuprofen
- bupivacaine e.g. diclofenac and ibuprofen
- capsaicin e.g. diclofenac and ibuprofen
- the dopant may be a fluorescent or radioactive or a metal (e.g. gold) tracer to study a biological process or monitor or diagnose a condition.
- the dopant is Lidocaine.
- the dopant which may be a hydrophobic material, a hydrophilic material, an oligo (DNA & RNA), or a protein, etc., may represent between about 0.01 and 50% of the weight or the volume of the particle, or between about 0.01 and 10%, 0.01 and 1 %, 0.01 and 0.5%, 0.01 and 0.1 %, 0.01 and 0.05%, 0.1 and 30%, 1 and 30%, 5 and 30%, 10 and 30%, 0.1 and 10%, 0.1 and 1 % or 1 and 10% of the weight or the volume of the particle, and may represent about 0.01 , 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1 , 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or 30% of the weight or the volume of the particle.
- the diameter of the particles may be somewhat dictated, although not necessarily, by the size of the electrospun nanofibres.
- the diameter of the particles should be such that the particles may be incorporated in the nanofibres of the mat without compromising the integrity of the fibres of the mat.
- the particle may have a diameter between about 1 nm and about 1000 nm. Although one would think that the particles should be smaller than the fibres, this is not imperative. It has been found that aggregates which are larger than the fibres can be incorporated inside the fibres given a swollen aspect of the fibres.
- the particle diameter is preferably ⁇ 1 .5 times the diameter of the fibres, more preferably smaller than the diameter of the fibres, and even more preferably 1 ⁇ 2 of the fibre diameter.
- the particles may be spherical, oblate spherical or may be ovoid or ellipsoid. They may be regular or irregular shaped. They may non-porous, or may be mesoporous or microporous. It may have a specific surface area of between about 2 and 400 m 2 /g, or between about 2 and 25, 2 and 20, 2 and 15, 2 and 10, 10 and 50, 10 and 25, 15 and 25 or 20 and 50m 2 /g, and may have a specific surface area of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 1 ,3 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 28, 30, 35, 40, 45 or 50 m 2 /g.
- the dopant is capable of being released from the particle, for example over a period of time.
- the release may be at a controlled or sustained rate.
- the particles may be capable of releasing the dopant over a period of between about 1 minute and 2 weeks.
- the rate of release of the dopant may be characterised by a half-release time, which is the time after which half of the original amount of hydrophobic material has been released.
- the particle(s) may have a half-release time of between about 1 minute and 96 hours.
- the particles may therefore be used in applications requiring sustained release over relatively short periods, for example between about 1 minute and about 1 hour, or they may be used in applications requiring sustained release over intermediate periods, for example between about 1 hour and about 1 day, or they may be used in applications requiring sustained release over relatively long periods, e.g. greater than 1 day.
- the particles may be in the form of a composition together with an acceptable carrier, diluent, excipient and/or adjuvant.
- the carrier may be a pharmaceutically acceptable carrier and the particles may be pharmaceutically acceptable
- the dopant is a veterinary substance
- the carrier may be a veterinarilly acceptable carrier and the particles may be veterinarilly acceptable
- the dopant is a biocidal substance
- the carrier may be a biocidally acceptable carrier and the particles may be biocidally acceptable
- the dopant is a cosmetic substance
- the carrier may be a cosmetically acceptable carrier and the particles may be cosmetically acceptable
- the dopant is a fungicidal substance
- the carrier may be a fungicidally acceptable carrier and the particles may be fungicidally acceptable.
- the encapsulation of dopant is achieved substantially in accordance with processes disclosed in International Publication No. WO 2006/133519, the content of which is incorporated herein in its entirety.
- the encapsulation may be achieved in accordance with the processes disclosed in International Publication Nos. WO 2001 /062232 WO 2006/050579, WO 2006/084339 and WO 2012/021922, which are also incorporated in their entirety. It has been surprisingly found that efficacy may be dramatically increased by including in the nanofibrous mat a combination of ceramic particles comprising a ceramic matrix and a dopant releasably encapsulated within said ceramic matrix and free dopant.
- the nanofibrous mat comprises additionally comprises free dopant dispersed throughout the nanofibres.
- the free dopant may be the same as or different to the encapsulated dopant.
- the free dopant is the same as the encapsulated dopant. Accordingly, in another aspect the invention provides a nanofibrous mat comprising:
- ceramic particles dispersed throughout said nanofibres and comprising a ceramic matrix and a dopant releasably encapsulated within said ceramic matrix;
- a method of forming a nanofibrous mat comprising:
- the method comprises adding dopant in powder form to the electrospinning solution; and electrospinning the electrospinning solution comprising the ceramic particles and dopant in powder form to form the nanofibrous mat having the ceramic particles and dopant dispersed throughout the formed electrospun nanofibers. This may advantageously increase the amount of dopant in the resulting layer.
- the electrospinning conditions may be selected generally depending on the nanofibres selected. Exemplary ranges for electrospinning parameters are provided in Table 1 below.
- FIG. 1 illustrates a flow diagram outlining a process for encapsulation of Lidocaine.
- FIG. 2 illustrates a graph of TGA/DTA analysis of particles containing Lidocaine.
- FIG. 3 illustrates a graph of Static light scattering analysis of particle containing Lidocaine.
- FIG. 4 illustrates a SEM image of particles containing Lidocaine.
- FIG. 5 illustrates a TEM image of particles containing Lidocaine.
- FIG. 6 illustrates the release profile of free and ceramic-encapsulated Lidocaine from fibres in the Sotax USP 4 system.
- FIG. 7 illustrates a Franz cell apparatus.
- FIG. 8 illustrates SEM images of nanofibres: A) Nanofibres with Lidocaine powder (5 000 x), B) Nanofibres with Lidocaine powder (25 000 x), C) Nanofibres with Lidocaine in spheres (5 000 x), D) Nanofibres with Lidocaine in spheres (25 000 x), E) Nanofibres with Lidocaine powder and Lidocaine in spheres (5 000 x), F) Nanofibres with Lidocaine powder and Lidocaine in spheres (25 000 x), G) PVA Nanofibres (5 000 x), H) PVA Nanofibres (25 000 x).
- FIG. 9 illustrates the permeation profile of Lidocaine through the human skin over 48 H-Comparison between nanofibre patches with free and/or ceramic encapsulated Lidocaine and the commercial patch.
- FIG. 10 illustrates a graph of quantity of Lidocaine released from the patches through the skin.
- FIG. 1 1 illustrates a graph of quantity of Lidocaine released from the patches in the dermis.
- FIG. 12 illustrates a graph of quantity of Lidocaine released from the patch in the epidermis.
- FIG. 13 illustrates a graph of quantity of remaining Lidocaine in the patch - comparison between nanofibre patches.
- FIG. 14 illustrates a graph of quantity of remaining Lidocaine in the patch - comparison between nanofibre patches and the commercial patch.
- FIG. 15 illustrates the permeation profile of free Lidocaine in water through human skin.
- FIG. 16 illustrates the release of Lidocaine (through the skin) at times earlier than 12 hours.
- FIG. 17 illustrates Lidocaine released through the skin at different times for up to 48 hours.
- FIGS. 18-19 illustrate Lidocaine released from the new batch of Lidocaine nanofibre mats over 24 hours in two separate experiments.
- FIG. 20 illustrates a comparison of the combination patch and the commercial patch as percentage (%) of Lidocaine permeated at 24 H through the human skin averaged over 4 separate studies.
- FIG. 21 illustrates the penetration of 60nm particles embedded in nanofibre mat in different layers of stratum corneum from human skin: the graph shows concentration of nanoparticles (calibrated to fluorescence levels) in various layers of stratum corneum over 24 hours.
- a surfactant solution was prepared by dissolving 54g of NP-15 in 400 mL of water.
- the APTES was hydrolysed by mixing 22.4 mL of APTES with 22.4 mL of water and allowed to cool. 12.8 g of Lidocaine was dissolved in 6.4 mL of THF, followed by the addition of 22.09 g of PTMS and 13.44 of TEOS.
- the Lidocaine/PTMS/TEOS mixture was added to the surfactant solution and allowed to fully mix. 60 minutes after the addition of the Lidocaine solution the hydrolysed APTES solution was added.
- the particles were aged overnight before being separated by centrifugation (10 minutes at 12,000 rpm) and collected for analysis and further experimentation. Analysis of particles
- the loading of the particles was determined using High Performance Liquid Chromatography (HPLC). For this, Lidocaine was leached form the particles using ethanol and the particles were subsequently removed from the solution by centrifugation. The supernatant was then analysed by HPLC to determine the loading. In the case of Lidocaine particles, the loading ranged from 10 - 15 wt %.
- Polyvinylalcohol is a synthetic hydrophilic polymer, which belongs to the group of vinyl polymers. PVA constitutes a simple chemical structure, which contains a functional hydroxyl group. It is soluble in polar solvents such as water. PVA is prepared by polymer-analogous hydrolysis or alcoholysis of polyvinyl acetate in methanol, when ester bonds are formed. Mowiol® 18-88 from Sigma Aldrich was used for the preparation of the polyvinyl alcohol solution. Electrospinninq
- PVA was dissolved in distilled water at an elevated temperature of 60°C with constant stirring for 24 hours to achieve a concentration of 12 wt %.
- Various amounts of Lidocaine in three forms were added into the PVA solutions.
- a QSonica sonicator was used for homogeneous dispersion of the Lidocaine in the PVA solutions.
- All solutions containing Lidocaine or Lidocain ceramic particles were electrospun using an electrospinning device. Nanofibers were collected on nonwowen textile. A needle with a 1 .6 mm diameter was used as the electrode.
- the aim was to optimize production to determine the maximum amount of lidocaine in the polymer solution that can be productively and effectively electrospun.
- the nanofibrous layers with the highest possible amounts of Lidocaine were made for tests using a Franz diffusion cell.
- Electrospinninq conditions All parameters of the electrospinning process are described in the following tables.
- HPLC was used for quantitative determination of the amount of released Lidocaine from nanofibres.
- HPLC separation is based on the separation of analytes according to their distribution between stationary (chromatographic column) and mobile phases (liquid).
- stationary chromatographic column
- mobile phases liquid.
- extracts from patches, from skin or the buffer were loaded onto a C18 reverse phase column and eluted in a mixture of acetonitrile and a 0.1 % triflouroacetic acid solution.
- a UV-Vis detector was used to quantify the amount of Lidocaine present.
- a skin membrane separates the donor (upper) cell part from the acceptor (the lower).
- the membrane lies on the bottom surface of the donor part.
- the test substance is placed in a suitable medium into the donor part.
- the acceptor is filled with an acceptor liquid (usually a buffer at pH 7.4). This part is continuously stirred and samples are periodically taken out and analysed. Instrumental analysis of the collected samples is usually performed by HPLC, radiography or scintigraphy, depending on the type of substance being investigated.
- Nanofibrous structures were analysed using scanning electron microscope (SEM) (Zeiss), after sputter coating with gold. Diameters of the electrospun fibres were analysed from the SEM images using image analysis software (NIS Elements). Diameters of nanofibres were up to 300 nm for all prepared layers (see Figure 8). Comparison of Lidocaine release from different types of nanofibrous mats using Franz cell method
- Lidocaine immobilised in various ways i.e. directly in nanofibres, in ceramic particles in nanofibres, etc.
- Human skin was used as the barrier membrane.
- Samples were subsequently analysed by HPLC.
- Phosphate buffered saline (PBS) with pH 7.4 was used as the acceptor buffer. It was continuously stirred at 32°C. Samples with an area of area 2 cm 2 were analysed for each nanofibre layer.
- the aim of the experiment was to obtain permeation profiles of immobilized Lidocaine from the nanofibrous layers through the human skin.
- Lidocaine was immobilized into a nanofibre layer directly by electrospinning Lidocaine powder in PVA or encapsulated Lidocaine in PVA, or Lidocaine was immobilized by a combination of these methods. Characteristics of the samples are shown in Table 6.
- a commercial patch "Versatis" containing Lidocaine was analysed with these samples. Residues of Lidocaine in nanofibrous layers (donor of Lidocaine) and in the skin (epidermis and dermis) were analysed after the experiment.
- the experiment schedule is schematically shown in Table 7.
- Lidocaine Permeation profiles of nanofibrous layers showed faster penetration through the skin in the first 12 hours than Lidocaine in aqueous solution. It is considered that this rapid transmission of Lidocaine could be due to degradation of PVA to metabolites (acetate esters, pyruvate, lactate, etc.), which are then transported into cells through active transport or passive diffusion. It is possible that Lidocaine penetrates with these metabolites (e.g. as an active symporter) or that these metabolites act as penetration enhancers for Lidocaine.
- the permeation profile of a commercial patch Versatis showed a linear release ( Figure 9) during the experiment (48hr).
- the amount of released Lidocaine in 12 hours was comparable to the amount of released Lidocaine from nanofibre samples 2 and 3 and about 4 fold lower than the combination patch (sample 4).
- the nanofibre mats were far superior to the commercial patch (70-85% vs. only 4.1 % released from the commercial patch).
- sample 4 released significantly higher quantities of Lidocaine at all times.
- the presence of encapsulated Lidocaine together with free Lidocaine enhanced the efficiency of Lidocaine release and permeation.
- combination sample 4 released more Lidocaine than the commercial sample at all times with only 25% undepleted Lidocaine versus 96% undepleted in the commercial patch at 48hr. It is possible that a different degradation profile of layers in the combination sample, due to synergistic effects of nanofibres with encapsulated Lidocaine, could lead to variations in permeation profiles during the transfer of Lidocaine into the skin from different types of mats. Further Studies
- FIG. 16-19 the performance of combination patches in three separate studies using different batches of polymer and Lidocaine particles in Franz cell experiments is illustrated.
- the permeation of Lidocaine from the combination patch and the commercial patch was measured through human skin (freshly obtained each time).
- the graph of Figure 16 shows release of Lidocaine (through the skin) at times earlier than 12 hours.
- the graph of Figure 17 shows Lidocaine released through the skin at different times for up to 48 hours.
- the graphs of Figures 18-19 depict Lidocaine released from a different batch of patches over 24 hours in two separate experiments.
- the data from these studies reinforces the superiority of the combination Lidocaine patch over the commercial patch.
- the data from these studies shows that release of Lidocaine from the combination patch starts as early as 2 hours (vs. >4 hours for the commercial patch) displaying Lidocaine release at levels many folds higher than that obtained for the commercial patch at all times. Notably, this is despite the fact that the Lidocaine loading in the combination patch was 60-100 fold less than that in the commercial patch of the same dimensions.
- the combination patch is consistently and significantly more efficient than the commercial patch, releasing approximately 80% of the payload at a higher release efficiency.
- Encapsulation of Lidocaine in a silica matrix was optimised using a modification of processes disclosed in International Publication No. WO 2006/133519 and Lidocaine loaded particles of appropriate size (approx. 60nm) were produced, characterised and successfully incorporated into nanofibre nonwoven mat.
- Three types of nanofibrous layers containing Lidocaine were made using the electrospinning method. Lidocaine was immobilized into nanofibrous layers directly by electrospinning of PVA solution with Lidocaine powder, a solution of PVA with particles containing Lidocaine, and a solution of PVA with a combination of Lidocaine powder and particles containing Lidocaine.
- the nanofibrous mats with Lidocaine led to improved permeation efficiencies in comparison to the commercial patch, Versatis.
- Versatis performed similarly to samples 2 and 3 and four times worse than sample 4 at 12hr.
- This enhanced permeability of the Lidocaine from nanofibre mats could be attributed to the biodegradable nature of the fibres and due to possible permeation enhancement by PVA metabolites.
- permeation profiles of nanofibrous layers with Lidocaine encapsulated in particles (sample 2) and Lidocaine powder (sample 3) were similar, indicating the permeation enhancing effect when particles containing Lidocaine are added to the fibres.
- sample 2 had more residual Lidocaine than sample 3, possibly indicating greater control of release of Lidocaine.
- the synergistic effect of the two technologies was especially noticeable when Lidocaine was immobilised into the nanofibrous layer as a combination of Lidocaine containing particles and free Lidocaine (sample 4).
- This sample showed a very unique permeation profile.
- the release rates of Lidocaine from sample 4 were superior to all types of mats including the commercial patch. This indicates the possibility of mutually beneficial effects of the two technologies.
- This layer showed 4 times higher release of Lidocaine through the skin than sample 2 and 3 after 12 hours. While the data showed a similar linear release of Lidocaine from sample 4 as from the commercial patch, much higher quantities were released at all times, with comparable accumulation in the deeper layers of the skin, namely the dermis.
- Nanofibres containing a combination of particles with encapsulated Lidocaine and Lidocaine powder showed a different permeation profile compared with nanofibres containing only particles with encapsulated Lidocaine (sample 2). This phenomenon may be due to the different degradation profile of layers in the presence of the loaded particles, or some other synergistic mechanism during the transfer of Lidocaine into the skin.
- nanofibre patches performed better than the commercial patch in terms of percentage release of Lidocaine through the skin at all times.
- a combination of loaded particles with nanofibres appears to significantly enhance the efficiency of Lidocaine permeation. While the exact mechanism needs to be elucidated, a combination of factors may play a role in this: biodegradable nature of the fibres, permeation enhancement of PVA metabolites or mechanistic feasibility due to physical incorporation of particles in the fibres.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Textile Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Manufacturing & Machinery (AREA)
- Mechanical Engineering (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Composite Materials (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019503596A JP7254017B2 (en) | 2016-04-05 | 2017-04-05 | Nanofiber mat containing ceramic particles with releasable dopants |
AU2017246999A AU2017246999B2 (en) | 2016-04-05 | 2017-04-05 | Nanofibrous mat containing ceramic particles with releasable dopant |
KR1020187032065A KR102371745B1 (en) | 2016-04-05 | 2017-04-05 | Nanofibrous mat containing ceramic particles with releasable dopant |
EP17778471.7A EP3440252A4 (en) | 2016-04-05 | 2017-04-05 | Nanofibrous mat containing ceramic particles with releasable dopant |
CN201780034755.5A CN109328249A (en) | 2016-04-05 | 2017-04-05 | Nanofiber mat containing the ceramic particle with releasable dopant therein |
US16/091,379 US20190343772A1 (en) | 2016-04-05 | 2017-04-05 | Nanofibrous mat containing ceramic particles with releasable dopant |
CA3019941A CA3019941A1 (en) | 2016-04-05 | 2017-04-05 | Nanofibrous mat containing ceramic particles with releasable dopant |
US17/705,627 US20230020948A1 (en) | 2016-04-05 | 2022-03-28 | Nanofibrous mat containing ceramic particles with releasable dopant |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016901261A AU2016901261A0 (en) | 2016-04-05 | Nanofibrous mat containing ceramic particles with releasable dopant | |
AU2016901261 | 2016-04-05 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/091,379 A-371-Of-International US20190343772A1 (en) | 2016-04-05 | 2017-04-05 | Nanofibrous mat containing ceramic particles with releasable dopant |
US17/705,627 Continuation US20230020948A1 (en) | 2016-04-05 | 2022-03-28 | Nanofibrous mat containing ceramic particles with releasable dopant |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017173487A1 true WO2017173487A1 (en) | 2017-10-12 |
Family
ID=60000189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2017/050289 WO2017173487A1 (en) | 2016-04-05 | 2017-04-05 | Nanofibrous mat containing ceramic particles with releasable dopant |
Country Status (8)
Country | Link |
---|---|
US (2) | US20190343772A1 (en) |
EP (1) | EP3440252A4 (en) |
JP (1) | JP7254017B2 (en) |
KR (1) | KR102371745B1 (en) |
CN (1) | CN109328249A (en) |
AU (1) | AU2017246999B2 (en) |
CA (1) | CA3019941A1 (en) |
WO (1) | WO2017173487A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109082774A (en) * | 2018-09-05 | 2018-12-25 | 华南理工大学 | A kind of anti-oxidant nano-fiber composite film and preparation method and application containing Folium Nerviliae fordii extract |
WO2021138710A1 (en) * | 2020-01-09 | 2021-07-15 | Sg Ventures Pty Limited | Substrate for use in a transdermal patch or dressing |
EP3515221B1 (en) * | 2016-09-19 | 2023-06-28 | Humanwellness SA | Cosmetic fabric |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3448928T3 (en) | 2016-04-29 | 2023-05-30 | Nanopareil Llc | HYBRID MEMBRANE COMPRISING CROSS-LINKED CELLULOSE |
EP3551789A4 (en) | 2016-12-12 | 2020-06-10 | Nanopareil, LLC | Spinnerets and spinneret arrays for electrospinning and electrospinning machines |
CN110923839B (en) * | 2019-11-21 | 2022-08-09 | 台州市旭泓服饰有限公司 | Elastic cotton textile fiber and preparation method thereof |
CN112647152A (en) * | 2020-12-17 | 2021-04-13 | 太和县昌达工贸有限公司 | Preparation process of biodegradable antibacterial polyester fiber |
CN112899890B (en) * | 2021-01-25 | 2022-02-18 | 浙江祥隆科技有限公司 | Nano SiO2 grafted polyacrylonitrile waterproof breathable fiber membrane and preparation method thereof |
KR20230116247A (en) * | 2022-01-28 | 2023-08-04 | 경북대학교 산학협력단 | Method for fabricating hot-water-dissolution resistant polymer blend nanofiber and hot-water-dissolution resistant polymer blend nanofiber fabricated by the same |
CN114470300A (en) * | 2022-03-28 | 2022-05-13 | 浙江蓝禾医疗用品有限公司 | Fluorescent nano dressing and preparation method thereof |
CN116271177B (en) * | 2023-05-23 | 2023-08-01 | 四川省医学科学院·四川省人民医院 | Nanofiber membrane wound dressing with stable photo-thermal effect and preparation method and application thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001062232A1 (en) | 2000-02-21 | 2001-08-30 | Australian Nuclear Science & Technology Organisation | Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use |
WO2006050579A1 (en) | 2004-11-15 | 2006-05-18 | Australian Nuclear Science & Technology Organisation | Solid particles from controlled destabilisation of microemulsions |
WO2006084339A1 (en) | 2005-02-14 | 2006-08-17 | Australian Nuclear Science & Technology Organisation | Layered nanoparticles |
WO2006133519A1 (en) | 2005-06-17 | 2006-12-21 | Australian Nuclear Science And Technology Organisation | Particles comprising a releasable dopant therein |
US7824601B1 (en) * | 2007-11-14 | 2010-11-02 | Abbott Cardiovascular Systems Inc. | Process of making a tubular implantable medical device |
WO2012021922A1 (en) | 2010-08-16 | 2012-02-23 | Australian Nuclear Science & Technology Organisation | Particulate substances comprising ceramic particles for delivery of biomolecules |
US20120136090A1 (en) * | 2009-07-10 | 2012-05-31 | Orthorebirth Co. Ltd. | Fiber wadding for filling bone defects |
WO2013023064A2 (en) * | 2011-08-09 | 2013-02-14 | New Jersey Institute Of Technology | Composite matrix for bone repair applications |
US20140335148A1 (en) * | 2013-05-07 | 2014-11-13 | Ho-Wang Tong | Bioactive substance-containing nanofibers and uses thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101130879B1 (en) * | 2002-04-04 | 2012-03-28 | 더 유니버시티 오브 아크론 | Non-woven fiber assemblies |
CN100408026C (en) * | 2003-01-24 | 2008-08-06 | 纽约州立大学研究基金会 | Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same |
US7592277B2 (en) * | 2005-05-17 | 2009-09-22 | Research Triangle Institute | Nanofiber mats and production methods thereof |
EP1855618A2 (en) * | 2005-03-07 | 2007-11-21 | Georgia Tech Research Corporation | Nanofilament scaffold for tissue regeneration |
EP1906915B1 (en) * | 2005-06-17 | 2017-09-27 | Australian Nuclear Science And Technology Organisation | Particles having hydrophobic material therein |
WO2009140381A1 (en) * | 2008-05-13 | 2009-11-19 | Research Triangle Institute | Porous and non-porous nanostructures and application thereof |
JP2012161363A (en) * | 2011-02-03 | 2012-08-30 | Yahashi Kogyo Kk | Floc with sustained-release property of silicon and calcium, and method of manufacturing the same |
JP2011015865A (en) * | 2009-07-10 | 2011-01-27 | Nagoya Institute Of Technology | Material for filling bone defect and production method thereof |
CN103099786A (en) * | 2013-01-06 | 2013-05-15 | 崔文国 | Preparation method of micro/nanofiber sustained release preparation |
CN103071188A (en) * | 2013-01-25 | 2013-05-01 | 上海市第六人民医院 | Cell factor loaded nanofiber membrane and preparation method thereof |
CN103074734B (en) * | 2013-01-31 | 2015-07-08 | 东华大学 | Preparation method for antibacterial nano-silver composite nanofiber mat by electrostatic spinning |
KR101616345B1 (en) * | 2013-07-12 | 2016-04-28 | 인하대학교 산학협력단 | Complex scaffold comprising nanofiber with nanoparticle to drug-delivery for artificial skin and filler, and method for preparing the same |
CN103611187A (en) * | 2013-11-15 | 2014-03-05 | 无锡中科光远生物材料有限公司 | Preparation method of tissue engineering scaffold for realizing time-ordered release of medicine |
-
2017
- 2017-04-05 KR KR1020187032065A patent/KR102371745B1/en active IP Right Grant
- 2017-04-05 US US16/091,379 patent/US20190343772A1/en not_active Abandoned
- 2017-04-05 CA CA3019941A patent/CA3019941A1/en active Pending
- 2017-04-05 JP JP2019503596A patent/JP7254017B2/en active Active
- 2017-04-05 AU AU2017246999A patent/AU2017246999B2/en active Active
- 2017-04-05 EP EP17778471.7A patent/EP3440252A4/en active Pending
- 2017-04-05 WO PCT/AU2017/050289 patent/WO2017173487A1/en active Application Filing
- 2017-04-05 CN CN201780034755.5A patent/CN109328249A/en active Pending
-
2022
- 2022-03-28 US US17/705,627 patent/US20230020948A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001062232A1 (en) | 2000-02-21 | 2001-08-30 | Australian Nuclear Science & Technology Organisation | Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use |
WO2006050579A1 (en) | 2004-11-15 | 2006-05-18 | Australian Nuclear Science & Technology Organisation | Solid particles from controlled destabilisation of microemulsions |
WO2006084339A1 (en) | 2005-02-14 | 2006-08-17 | Australian Nuclear Science & Technology Organisation | Layered nanoparticles |
WO2006133519A1 (en) | 2005-06-17 | 2006-12-21 | Australian Nuclear Science And Technology Organisation | Particles comprising a releasable dopant therein |
US7824601B1 (en) * | 2007-11-14 | 2010-11-02 | Abbott Cardiovascular Systems Inc. | Process of making a tubular implantable medical device |
US20120136090A1 (en) * | 2009-07-10 | 2012-05-31 | Orthorebirth Co. Ltd. | Fiber wadding for filling bone defects |
WO2012021922A1 (en) | 2010-08-16 | 2012-02-23 | Australian Nuclear Science & Technology Organisation | Particulate substances comprising ceramic particles for delivery of biomolecules |
WO2013023064A2 (en) * | 2011-08-09 | 2013-02-14 | New Jersey Institute Of Technology | Composite matrix for bone repair applications |
US20140335148A1 (en) * | 2013-05-07 | 2014-11-13 | Ho-Wang Tong | Bioactive substance-containing nanofibers and uses thereof |
Non-Patent Citations (5)
Title |
---|
CHEN, DAVE W.YUNG-HENG HSUJUN-YI LIAOSHIH-JUNG LIUJAN-KAN CHENSTEVE WEN-NENG UENG: "Sustainable release of vancomycin, gentamicin and lidocaine from novel electrospun sandwich-structured PLGA/collagen nanofibrous membranes", INTERNATIONAL JOURNAL OF PHARMACEUTICS., vol. 430, 2012, pages 335 - 341, XP028483463, DOI: 10.1016/j.ijpharm.2012.04.010 |
See also references of EP3440252A4 |
TSENG, YYWA CHENJY LIAOYC KAOSJ LIU: "Biodegradable poly([D,L]-lactide-co-glycolide) nanofibers for the sustainable delivery of Lidocaine into the epidural space after laminectomy", NANOMEDICINE, vol. 9, 2014, pages 77 - 87 |
WEINIGER, C. F.L. GOLOVANEVSKIA. J. DOMBD. ICKOWICZ: "Extended release formulations for local anaesthetic agents.", ANAESTHESIA, vol. 67, no. 8, 2012, pages 906 - 916, XP055636710, DOI: 10.1111/j.1365-2044.2012.07168.x |
XIN ZHAO ET AL.: "Tumor-Triggered Controlled Drug Release from Electrospun Fibers Using Inorganic Caps for Inhibiting Cancer Relapse", SMALL, vol. 11, no. 34, 2016, pages 4284 - 4291, XP055633364, DOI: 10.1002/smll.201500985 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3515221B1 (en) * | 2016-09-19 | 2023-06-28 | Humanwellness SA | Cosmetic fabric |
CN109082774A (en) * | 2018-09-05 | 2018-12-25 | 华南理工大学 | A kind of anti-oxidant nano-fiber composite film and preparation method and application containing Folium Nerviliae fordii extract |
WO2021138710A1 (en) * | 2020-01-09 | 2021-07-15 | Sg Ventures Pty Limited | Substrate for use in a transdermal patch or dressing |
Also Published As
Publication number | Publication date |
---|---|
US20190343772A1 (en) | 2019-11-14 |
CA3019941A1 (en) | 2017-10-12 |
AU2017246999B2 (en) | 2022-12-08 |
AU2017246999A1 (en) | 2018-09-13 |
EP3440252A1 (en) | 2019-02-13 |
CN109328249A (en) | 2019-02-12 |
JP7254017B2 (en) | 2023-04-07 |
US20230020948A1 (en) | 2023-01-19 |
JP2019513513A (en) | 2019-05-30 |
KR20190021205A (en) | 2019-03-05 |
KR102371745B1 (en) | 2022-03-07 |
EP3440252A4 (en) | 2019-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230020948A1 (en) | Nanofibrous mat containing ceramic particles with releasable dopant | |
Ulubayram et al. | Nanofibers based antibacterial drug design, delivery and applications | |
Valenta et al. | The use of polymers for dermal and transdermal delivery | |
EP2644191B1 (en) | Nonwoven membrane as a drug delivery system | |
Lee et al. | Long acting injectable formulations: the state of the arts and challenges of poly (lactic-co-glycolic acid) microsphere, hydrogel, organogel and liquid crystal | |
JP2019502652A (en) | Reduced and oxidized polysaccharides and methods of their use | |
JP5809624B2 (en) | Fulvestrant nanospheres / microspheres and their preparation and use | |
Maleki et al. | Drug release behavior of electrospun twisted yarns as implantable medical devices | |
CN103040727A (en) | Preparation method of drug and protein sustained-release alginate hybrid gel | |
CN103520007A (en) | Skin active factor flexible nano-liposome and preparation method and application thereof | |
Duan et al. | Polymeric nanofibers for drug delivery applications: a recent review | |
Gaydhane et al. | Electrospun nanofibres in drug delivery: advances in controlled release strategies | |
JP2018510883A (en) | Dissolvable microniddle for protein or peptide delivery | |
CN102995295B (en) | Panax pseudo-ginseng non-woven fabrics and method for preparing same | |
Wang et al. | Synthesis, antimicrobial and release of chloroamphenicol loaded poly (l-lactic acid)/ZrO2 nanofibrous membranes | |
EP3583954A1 (en) | Nanodispersions of birch bark extract, electrospun fibers containing such nanodispersions and their use for the treatment of wounds | |
Sahu et al. | Nanofibers in drug delivery | |
Wei et al. | Functional nanofibers for drug delivery applications | |
Yan et al. | Dual drug-loaded core-shell nanofibers membranes via emulsion electrospinning and their controllable sustained release property | |
CN113896906B (en) | Charge-guided micro-nano adherable hydrogel and preparation method and application thereof | |
TW201714610A (en) | Soluble microneedle for protein or peptide | |
Briggs et al. | Growth factor delivery from electrospun materials | |
Ezzati et al. | Fabrication and evaluating the potentials of minocycline hydrochloride-loaded nanofibrous membranes in periodontal guided tissue regeneration: In vivo release and biocompatibility analysis | |
JP2013010704A (en) | Nanoparticle for iontophoresis and method of manufacturing the same | |
KR101444067B1 (en) | Manufacturing method of drug loaded polyurethane composite membrane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2017246999 Country of ref document: AU Date of ref document: 20170405 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019503596 Country of ref document: JP Kind code of ref document: A Ref document number: 3019941 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187032065 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017778471 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017778471 Country of ref document: EP Effective date: 20181105 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17778471 Country of ref document: EP Kind code of ref document: A1 |